Edgewise Therapeutics, Inc. Operating Expenses
Edgewise Therapeutics, Inc. (EWTX) reported Operating Expenses of $61.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Edgewise Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $61.94M, a 45.37% increase year-over-year.
- Edgewise Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $54.12M, a 17.75% increase year-over-year.
- Edgewise Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $55.98M, a 22.92% increase year-over-year.
- Edgewise Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $46.86M, a 15.89% increase year-over-year.
- Edgewise Therapeutics, Inc. operating expenses for fiscal 2025 was $191.41M, a 20.51% increase from fiscal 2024.
- Edgewise Therapeutics, Inc. operating expenses for fiscal 2024 was $158.83M, a 38.89% increase from fiscal 2023.
- Edgewise Therapeutics, Inc. operating expenses for fiscal 2023 was $114.36M, a 59.59% increase from fiscal 2022.
- Edgewise Therapeutics, Inc. operating expenses for fiscal 2022 was $71.66M, a 65.82% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $61.94M 10-Q · filed 2026-08-06 | $116.06M 10-Q · filed 2026-08-06 | $172.04M derived: sum of 3 quarters · filed 2026-08-06 | $218.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $54.12M 10-Q · filed 2026-05-07 | $110.09M derived: sum of 2 quarters · filed 2026-05-07 | $156.95M derived: sum of 3 quarters · filed 2026-05-07 | $199.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $55.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $102.84M derived: sum of 2 quarters · filed 2026-02-26 | $145.45M derived: sum of 3 quarters · filed 2026-08-06 | $191.41M 10-K · filed 2026-02-26 |
| 2025-09-30 | $46.86M 10-Q · filed 2025-11-06 | $89.47M derived: sum of 2 quarters · filed 2026-08-06 | $135.43M 10-Q · filed 2025-11-06 | $180.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $42.61M 10-Q · filed 2026-08-06 | $88.57M 10-Q · filed 2026-08-06 | $134.11M derived: sum of 3 quarters · filed 2026-08-06 | $174.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $45.96M 10-Q · filed 2026-05-07 | $91.50M derived: sum of 2 quarters · filed 2026-05-07 | $131.93M derived: sum of 3 quarters · filed 2026-05-07 | $170.04M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $45.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $85.97M derived: sum of 2 quarters · filed 2026-02-26 | $124.08M derived: sum of 3 quarters · filed 2026-02-26 | $158.83M 10-K · filed 2026-02-26 |
| 2024-09-30 | $40.43M 10-Q · filed 2025-11-06 | $78.54M derived: sum of 2 quarters · filed 2025-11-06 | $113.29M 10-Q · filed 2025-11-06 | $147.15M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $38.11M 10-Q · filed 2025-08-07 | $72.86M 10-Q · filed 2025-08-07 | $106.72M derived: sum of 3 quarters · filed 2026-02-26 | $136.17M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $34.75M 10-Q · filed 2025-05-08 | $68.61M derived: sum of 2 quarters · filed 2026-02-26 | $98.07M derived: sum of 3 quarters · filed 2026-02-26 | $123.41M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $33.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $63.31M derived: sum of 2 quarters · filed 2026-02-26 | $88.65M derived: sum of 3 quarters · filed 2026-02-26 | $114.36M 10-K · filed 2026-02-26 |
| 2023-09-30 | $29.45M 10-Q · filed 2024-11-07 | $54.79M derived: sum of 2 quarters · filed 2024-11-07 | $80.50M 10-Q · filed 2024-11-07 | $102.57M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $25.34M 10-Q · filed 2024-08-08 | $51.04M 10-Q · filed 2024-08-08 | $73.12M derived: sum of 3 quarters · filed 2024-08-08 | $91.38M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $25.70M 10-Q · filed 2024-05-09 | $47.78M derived: sum of 2 quarters · filed 2024-05-09 | $66.05M derived: sum of 3 quarters · filed 2024-05-09 | $82.54M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $22.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $40.34M derived: sum of 2 quarters · filed 2024-02-22 | $56.83M derived: sum of 3 quarters · filed 2024-02-22 | $71.66M 10-K · filed 2024-02-22 |
| 2022-09-30 | $18.26M 10-Q · filed 2023-11-09 | $34.75M derived: sum of 2 quarters · filed 2023-11-09 | $49.58M 10-Q · filed 2023-11-09 | $62.40M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $16.49M 10-Q · filed 2023-08-10 | $31.32M 10-Q · filed 2023-08-10 | $44.14M derived: sum of 3 quarters · filed 2023-08-10 | $57.22M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $14.83M 10-Q · filed 2023-05-11 | $27.65M derived: sum of 2 quarters · filed 2023-05-11 | $40.72M derived: sum of 3 quarters · filed 2023-05-11 | $51.18M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $12.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $25.90M derived: sum of 2 quarters · filed 2023-02-23 | $36.36M derived: sum of 3 quarters · filed 2023-02-23 | $43.22M 10-K · filed 2023-02-23 |
| 2021-09-30 | $13.08M 10-Q · filed 2022-11-03 | $23.54M derived: sum of 2 quarters · filed 2022-11-03 | $30.39M 10-Q · filed 2022-11-03 | $36.74M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $10.46M 10-Q · filed 2022-08-04 | $17.32M 10-Q · filed 2022-08-04 | $23.66M derived: sum of 3 quarters · filed 2022-08-04 | $27.30M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $6.86M 10-Q · filed 2022-05-11 | $13.20M derived: sum of 2 quarters · filed 2022-05-11 | $16.84M derived: sum of 3 quarters · filed 2022-05-11 | $20.80M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $6.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $9.99M derived: sum of 2 quarters · filed 2022-02-24 | $13.94M derived: sum of 3 quarters · filed 2022-02-24 | $17.19M 10-K · filed 2022-02-24 |
| 2020-09-30 | $3.64M 10-Q · filed 2021-11-10 | $7.60M derived: sum of 2 quarters · filed 2021-11-10 | $10.85M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $3.96M 10-Q · filed 2021-08-09 | $7.21M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $3.25M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |